Sector Watch: Healthcare - Oct 01 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $121.17 -0.77 -0.63% | XBI: $94.59 -1.28 -1.34% | Updated Oct 01, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| VRX52WH Valeant Pharmaceuticals International $64.3M |
0.18+0.04 7.2 M 5.7x |
30% | ||
| CRMD52WH CorMedix Inc $116.4M |
1.19+0.22 16.4 M 5.7x |
23% | ||
| NEPT Neptune Technologies & Bioresources Inc $308.5M |
4.60+0.72 11.7 M 4.5x |
19% | ||
| TRVN Trevena $178.8M |
2.35+0.23 4.1 M 2.0x |
11% | ||
| HRT Arrhythmia Research Technology $255.8M |
0.45+0.04 456.9 K |
10% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| AKRX52WL Akorn $672.4M |
5.36-7.62 27.5 M 11.1x |
-59% | ||
| OMER Omeros $677.9M |
13.96-10.45 3.6 M 5.6x |
-43% | ||
| INSM52WL Insmed $1.2B |
15.74-4.48 6.8 M 9.1x |
-22% | ||
| CSBR52WH Champions Oncology $160.8M |
14.40-3.07 1.0 M 3.3x |
-18% | ||
| MRNS52WH Marinus Pharmaceuticals $350.5M |
8.65-1.35 2.0 M 3.2x |
-14% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Akorn Comments on Delaware Chancery Court Ruling | Business Wire [businesswire.com]Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® | Business Wire [businesswire.com]
Insmed to Present at Two October Conferences [globenewswire.com]
Trevena announces completion of leadership transition and appointment of new director [globenewswire.com]
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options [globenewswire.com]
Bronchiectasis - 2018 Pipeline Insight Report - ResearchAndMarkets.com | Business Wire [businesswire.com]
FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation [prnewswire.com]
Omeros to Present at the 2018 Cantor Global Healthcare Conference | Business Wire [businesswire.com]
Alcohol Addiction Pipeline Review, H2 2018 - Therapeutic Assessment of 30 Companies - ResearchAndMarkets.com | Business Wire [businesswire.com]
Restless Legs Syndrome Pipeline Review, H2 2018 - Therapeutic Assessment of 6 Companies - ResearchAndMarkets.com | Business Wire [businesswire.com]
Global Post-Operative Pain Pipeline Review, H2 2018 - Therapeutic Assessment of 40 Companies - ResearchAndMarkets.com | Business Wire [businesswire.com]
Drug Addiction Pipeline Review, H2 2018 - Therapeutic Assessment of 25 Companies & Drug Profile Activity - ResearchAndMarkets.com | Business Wire [businesswire.com]
Autism - Pipeline Review, H2 2018 - Therapeutic Analysis of 22 Companies & Drug Profiles - ResearchAndMarkets.com | Business Wire [businesswire.com]
Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference [globenewswire.com]
Marinus Completes Enrollment in its Magnolia Postpartum Depression Study [globenewswire.com]
Retinopathy Of Prematurity - Pipeline Review, H2 2018 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Aberdeen Income Credit Strategies Fund(1) Announces Performance Data And Portfolio Composition [prnewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
